 Released: Jun 4, 2008
Expires: Jun 4, 2009
Type: Audio
Over 75 million US adults have cardiovascular disease (CVD), the leading cause of death in the United States. Of those individuals with CVD, approximately 17 million have coronary artery disease (CAD), leading to more than 500,000 deaths annually. According to the American Heart Association (AHA), CAD accounts for the largest portion of the annual CVD-related US healthcare burden...
|
- CPE Credits/Hours: 1.00
- CME Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
Released: Jun 2, 2008
Expires: Jun 2, 2009
Type: Audio
Over 75 million US adults have cardiovascular disease (CVD), the leading cause of death in the United States. Of those individuals with CVD, approximately 17 million have coronary artery disease (CAD), leading to more than 500,000 deaths annually. According to the American Heart Association (AHA), CAD accounts for the largest portion of the annual CVD-related US healthcare burden...
|
- CME Credits/Hours: 1.00
- CPE Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
Released: Feb 28, 2008
Expires: Feb 28, 2009
Type: Video
This presentation aims to focus on current strategies to optimize oral antiplatelet agents in the treatment of ACS and PCI. Topics addressed include current limitations with clopidogrel, variability in response to clopidogrel and the clinical outcomes associated with poor response, and strategies to reduce variability. Finally, a comparison of the biologic response of prasugrel and...
|
- CME Credits/Hours: 0.50
- Cost: Free
-
System Requirements:
|
Released: Feb 28, 2008
Expires: Feb 28, 2009
Type: Video
This presentation focuses on the results of the TRITON-TIMI 38 trial, which examines the use of the investigational thienopyridine prasugrel compared to clopidogrel in patients with ACS who were undergoing primary PCI. Highlighted data from the trial is presented, including several in-depth analyses investigating sub-populations as it relates to ischemic endpoints as well as...
|
- CME Credits/Hours: 1.00
- Cost: Free
-
System Requirements:
|
Released: Feb 28, 2008
Expires: Feb 28, 2009
Type: Video
This presentation aims to address the central role of platelets in acute coronary syndromes (ACS) and the use of both oral antiplatelet therapy and interventional therapy as cornerstones for the treatment of ACS. Topics to be discussed include the pharmacology of approved and investigational oral antiplatelet agents, clinical trial data detailing the use of...
|
- CME Credits/Hours: 0.50
- Cost: Free
-
System Requirements:
|
Released: Feb 19, 2008
Expires: Feb 19, 2009
Type: Video
Biologic agents that block TNF have proven highly effective in improving the signs and symptoms of rheumatoid arthritis (RA), preventing the progression of joint damage, and improving functional status and quality of life. The introduction of TNF inhibitors has helped elevate the goals of treating RA, such that low disease activity or even remission are commonly considered...
|
- CME Credits/Hours: 0.50
- CPE Credits/Hours: 0.50
- CNE Credits/Hours: 0.50
- Cost: Free
-
System Requirements:
|
Released: Nov 7, 2007
Expires: Nov 7, 2008
Type: Video
Many therapies currently exist today for the treatment of hypertension, however, there still remains a critical need to better establish and define the concept of vascular protection. To appreciate this concept, it is important to understand the data which results in a reduction in the risk of cardiovascular outcomes (MI, stroke or death) associated with some treatment regimens....
|
- CME Credits/Hours: 0.75
- Cost: Free
-
System Requirements:
|
|
